Immuneering Corp
IMRXNasdaq
$4.64
↓ -2.9%Jul 17 close · end-of-day
Price
1Y↑ +17.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$300.0M
Enterprise Value
$252.7M
P/E
—
P/S
—
P/B
1.5
EV/EBITDA
—
PEG
—
FCF Yield
-16.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$54.4M
Free Cash Flow (TTM)
-$49.9M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-26.4%
ROIC
-29.4%
Debt / Equity
—
Net Cash
$47.3M
Return 1Y
+7.9%
Company profile
Immuneering Corporation focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer.
- CEO
- Benjamin J. Zeskind
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- Massachusetts
- Website
- immuneering.com
Management & directors
- Zeskind Benjamin J.PRESIDENT AND CEO
- Hall Brett MatthewCHIEF SCIENTIFIC OFFICER
- Neufeld Leah RCHIEF PEOPLE OFFICER
- Brakewood Harold EugeneChief Business Officer
- Bookman MichaelCHIEF LEGAL OFFICER, SECRETARY
- Morales MalloryChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
IMRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.21↓ -50.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | $2.1M | $316,952.00 | $0.00 | — | — |
| Gross profit | $1.0M | $926,888.00 | $158,830.00 | $0.00 | — | — |
| Operating income | -$17.1M | -$33.9M | -$51.7M | -$58.4M | -$64.1M | -$59.4M |
| Net income | -$17.0M | -$33.5M | -$50.5M | -$53.5M | -$61.0M | -$56.0M |
| Diluted EPS | -$3.44 | -$2.46 | -$1.91 | -$1.88 | -$2.04 | -$1.27 |
| Operating cash flow | -$14.6M | -$30.9M | -$44.1M | -$49.0M | -$55.0M | -$45.3M |
| Free cash flow | -$14.7M | -$30.9M | -$44.8M | -$49.3M | -$55.1M | -$45.5M |
| Gross margin | 44.6% | 44.6% | 50.1% | — | — | — |
| Operating margin | -739.0% | -1629.2% | -16325.8% | — | — | — |
| Net margin | -737.2% | -1612.3% | -15937.3% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$14.9M | -$15.3M | -$18.6M | -$15.5M | -$14.8M | -$15.4M | -$13.8M | -$15.3M |
| Net income | -$14.1M | -$14.6M | -$18.1M | -$15.0M | -$14.4M | -$15.0M | -$11.6M | -$13.5M |
| Diluted EPS | -$0.47 | -$0.49 | -$0.59 | -$0.42 | -$0.40 | -$0.38 | -$0.07 | -$0.21 |
| Operating cash flow | -$11.5M | -$13.5M | -$14.5M | -$14.1M | -$9.4M | -$12.0M | -$9.8M | -$18.4M |
| Free cash flow | -$11.6M | -$13.5M | -$14.5M | -$14.1M | -$9.4M | -$12.0M | -$10.0M | -$18.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-23 | Zeskind Benjamin J.· PRESIDENT AND CEO | Buy | 2,400 | $4.56 | $10,948.08 | filing |
| 2026-06-15 | Hall Brett Matthew· CHIEF SCIENTIFIC OFFICER | Buy | 6,035 | $4.15 | $25,045.25 | filing |
| 2026-03-13 | Neufeld Leah R· CHIEF PEOPLE OFFICER | Award | 3,628 | $4.29 | $15,573.19 | filing |
| 2026-01-16 | Brakewood Harold Eugene· Chief Business Officer | Buy | 5,250 | $4.76 | $24,990.00 | filing |
| 2026-01-15 | Schall Thomas J. | Buy | 21,645 | $4.67 | $101,041.02 | filing |
| 2026-01-15 | Hall Brett Matthew· CHIEF SCIENTIFIC OFFICER | Buy | 2,298 | $4.57 | $10,501.86 | filing |
| 2026-01-13 | Neufeld Leah R· CHIEF PEOPLE OFFICER | Buy | 2,626 | $4.15 | $10,905.78 | filing |
| 2026-01-12 | Feinberg Peter | Buy | 20,000 | $4.35 | $86,904.00 | filing |
| 2025-10-03 | Feinberg Peter | Buy | 7,500 | $6.67 | $50,025.00 | filing |
| 2025-10-01 | Bookman Michael· CHIEF LEGAL OFFICER, SECRETARY | Buy | 1,020 | $6.83 | $6,966.50 | filing |
| 2025-10-01 | Neufeld Leah R· CHIEF PEOPLE OFFICER | Buy | 800 | $6.38 | $5,103.36 | filing |
| 2025-10-01 | Morales Mallory· Chief Accounting Officer | Buy | 300 | $6.39 | $1,917.00 | filing |
| 2025-09-30 | Feinberg Peter | Buy | 7,500 | $7.03 | $52,730.25 | filing |
| 2025-09-29 | Feinberg Peter | Buy | 5,000 | $7.18 | $35,900.00 | filing |
| 2025-09-15 | Hall Brett Matthew· CHIEF SCIENTIFIC OFFICER | Award | 14,880 | $1.43 | $21,248.64 | filing |
| 2025-09-15 | Morales Mallory· Chief Accounting Officer | Award | 14,497 | $1.43 | $20,701.72 | filing |
| 2025-09-15 | Neufeld Leah R· CHIEF PEOPLE OFFICER | Award | 11,815 | $1.43 | $16,871.82 | filing |
| 2025-07-02 | Zeskind Benjamin J.· PRESIDENT AND CEO | Buy | 7,015 | $3.53 | $24,792.41 | filing |
| 2025-07-02 | HAUSMAN DIANA | Buy | 3,000 | $3.62 | $10,873.50 | filing |
| 2025-07-02 | HAUSMAN DIANA | Buy | 2,500 | $3.60 | $8,989.00 | filing |
| 2025-07-02 | Neufeld Leah R· CHIEF PEOPLE OFFICER | Buy | 700 | $3.57 | $2,498.65 | filing |
| 2025-07-01 | Zeskind Benjamin J.· PRESIDENT AND CEO | Buy | 2,985 | $3.38 | $10,086.91 | filing |
| 2025-06-27 | Schall Thomas J. | Buy | 9,500 | $3.66 | $34,788.05 | filing |
| 2025-06-23 | Hall Brett Matthew· CHIEF SCIENTIFIC OFFICER | Buy | 6,007 | $2.43 | $14,596.41 | filing |
| 2025-06-20 | Hall Brett Matthew· CHIEF SCIENTIFIC OFFICER | Buy | 7,415 | $2.70 | $20,019.76 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.